Physician profile
Stephen E Depasquale
NPI 1801848320
$4,389.27
in general payments reported to CMS, 2019-2025
26 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $651 · 2021: $166 · 2022: $507 · 2023: $667 · 2024: $984 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.61 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $726.14 | 2020-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $575.04 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $495.86 | 2019-2025 | Lynparza |
| Intuitive Surgical, INC. | $442.92 | 2019-2023 | |
| Eisai INC. | $413.94 | 2019-2025 | |
| Abbvie INC. | $348.24 | 2019-2025 | |
| Daiichi Sankyo INC. | $248.79 | 2024-2025 | Enhertu, Injectafer |
| Seagen INC. | $162.74 | 2022-2023 | Tivdak |
| Astellas Pharma US INC | $129.16 | 2023-2025 | Veozah |
| Baxter Healthcare | $115.31 | 2019-2025 | Perclot, Adept |
| Dexcom, INC. | $111.57 | 2023 | Dexcom G7 Gss (161) |
| Axonics, INC. | $110.45 | 2023 | Bulkamid, Axonics |
| Clovis Oncology, INC. | $103.67 | 2019-2020 | |
| Amgen INC. | $88.63 | 2019-2022 | |
| Conmed Corporation | $76.36 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $65.92 | 2024-2025 | Stravix Pl, Grafix Xc, Oasis |
| Tempus Ai, INC | $29.67 | 2024 | Xt Cdx |
| Genentech USA, INC. | $28.08 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.28 | 2022 | |
| Pfizer INC. | $22.54 | 2024 | |
| Cardinal Health 414 LLC | $21.95 | 2023 | |
| Avanos Medical | $19.74 | 2019 | |
| Hologic Sales and Service, LLC | $14.69 | 2024 | Myosure Tissue Removal Device |
| Lilly USA, LLC | $14.58 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Depasquale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.